Combination Strategies A Common Thread In NASH R&D
Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.
You may also be interested in...
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.
The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of a trial in portal hypertension.
Madrigal’s selective THR beta agonist continues to demonstrate hepatic fat-lowering abilities in 36-week data, along with lipid-lowering characteristics. The company hopes to initiate a Phase III study in early 2019.